KR102146340B1 - 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법 - Google Patents

항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법 Download PDF

Info

Publication number
KR102146340B1
KR102146340B1 KR1020147030138A KR20147030138A KR102146340B1 KR 102146340 B1 KR102146340 B1 KR 102146340B1 KR 1020147030138 A KR1020147030138 A KR 1020147030138A KR 20147030138 A KR20147030138 A KR 20147030138A KR 102146340 B1 KR102146340 B1 KR 102146340B1
Authority
KR
South Korea
Prior art keywords
hcmv
fluorescence
virus
cells
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147030138A
Other languages
English (en)
Korean (ko)
Other versions
KR20140146630A (ko
Inventor
데이비드 이. 앤더슨
자스민카 보직
바르텔레미 온트소카
Original Assignee
배리에이션 바이오테크놀로지스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 배리에이션 바이오테크놀로지스 아이엔씨. filed Critical 배리에이션 바이오테크놀로지스 아이엔씨.
Priority to KR1020207021568A priority Critical patent/KR102314245B1/ko
Publication of KR20140146630A publication Critical patent/KR20140146630A/ko
Application granted granted Critical
Publication of KR102146340B1 publication Critical patent/KR102146340B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G01N2333/045—Cytomegalovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020147030138A 2012-03-27 2013-03-27 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법 Expired - Fee Related KR102146340B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207021568A KR102314245B1 (ko) 2012-03-27 2013-03-27 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616204P 2012-03-27 2012-03-27
US61/616,204 2012-03-27
PCT/IB2013/001021 WO2013144722A2 (en) 2012-03-27 2013-03-27 Methods for detection of anti-cytomegalovirus neutralizing antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207021568A Division KR102314245B1 (ko) 2012-03-27 2013-03-27 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법

Publications (2)

Publication Number Publication Date
KR20140146630A KR20140146630A (ko) 2014-12-26
KR102146340B1 true KR102146340B1 (ko) 2020-08-24

Family

ID=49261346

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147030138A Expired - Fee Related KR102146340B1 (ko) 2012-03-27 2013-03-27 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법
KR1020207021568A Expired - Fee Related KR102314245B1 (ko) 2012-03-27 2013-03-27 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207021568A Expired - Fee Related KR102314245B1 (ko) 2012-03-27 2013-03-27 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법

Country Status (11)

Country Link
US (2) US10006096B2 (enExample)
EP (2) EP2831285B1 (enExample)
JP (1) JP6265344B2 (enExample)
KR (2) KR102146340B1 (enExample)
CN (2) CN119716047A (enExample)
AU (2) AU2013239383B2 (enExample)
BR (1) BR112014023913B1 (enExample)
CA (1) CA2867789C (enExample)
MX (1) MX354822B (enExample)
RU (1) RU2660712C2 (enExample)
WO (1) WO2013144722A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102146340B1 (ko) * 2012-03-27 2020-08-24 배리에이션 바이오테크놀로지스 아이엔씨. 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
JP6850483B2 (ja) * 2018-03-06 2021-03-31 株式会社ＣｅＳＰＩＡ Ｃｅｌｌ−ｂａｓｅｄ ａｓｓａｙ法に基づいたハイスループット抗体検出方法
WO2019232453A1 (en) * 2018-06-01 2019-12-05 Gravid Therapies, Inc. Methods, kits, and products for detection of cytomegalovirus infection
WO2020036811A1 (en) * 2018-08-14 2020-02-20 Merck Sharp & Dohme Corp. A virus neutralization assay utilizing imaging cytometry
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN111474339A (zh) * 2020-04-17 2020-07-31 浙江康佰裕生物科技有限公司 一种利用荧光标记痘病毒颗粒的方法及其应用
TWI871709B (zh) 2020-06-21 2025-02-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CN112362649B (zh) * 2020-11-09 2024-07-12 长春金赛药业有限责任公司 一种rhGH中和抗体的检测方法
CN112945919B (zh) * 2021-01-29 2023-04-28 上海睿钰生物科技有限公司 一种病毒中和抗体的检测方法、系统及其应用
CN114859046B (zh) * 2021-04-30 2025-11-28 中国人民解放军军事科学院军事医学研究院 含高效价抗hcmv中和抗体原料血浆的筛选方法和抗hcmv中和抗体效价的检测方法
US20250157651A1 (en) * 2022-01-19 2025-05-15 Trustees Of Dartmouth College Systems and methods for deterring viral transmission using neural networks
WO2023154857A2 (en) * 2022-02-11 2023-08-17 Trustees Of Dartmouth College Systems and methods for identifying and treating primary and latent infections and/or determining time since infection
CN119192349A (zh) * 2024-07-18 2024-12-27 北京市延庆区疾病预防控制中心 用于检测黄连素抗性病毒的试剂及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100267583A1 (en) 2009-04-15 2010-10-21 Variation Biotechnologies Inc. Method and kit for detection of hepatitis a virus neutralizing antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
US5248768A (en) * 1986-11-24 1993-09-28 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus
JPH06222062A (ja) 1993-01-22 1994-08-12 Teijin Ltd ウイルス感染価および中和抗体価の測定法
DE19910044A1 (de) 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
US6569616B1 (en) * 1999-07-29 2003-05-27 Wisconsin Alumni Research Foundation Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate
US6849409B2 (en) * 2000-10-16 2005-02-01 Axxima Pharmaceuticals Ag Cellular kinases involved in Cytomegalovirus infection and their inhibition
WO2004058166A2 (en) 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
PT1651666E (pt) 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
CN1686541A (zh) * 2005-04-11 2005-10-26 王明丽 人巨细胞病毒pp65蛋白质疫苗的制备方法
CN101522213A (zh) * 2006-09-01 2009-09-02 Csl有限公司 引起或诱导免疫应答的方法
US9439960B2 (en) * 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
AU2008359583B2 (en) * 2008-07-16 2012-04-05 Institute For Research In Biomedicine Human cytomegalovirus neutralising antibodies and use thereof
US9145577B2 (en) 2010-08-10 2015-09-29 The Research Foundation Of State University Of New York Lipoprotein lipase assay
JP6232544B2 (ja) 2011-11-11 2017-11-22 ヴァリエーション バイオテクノロジーズ インコーポレイテッド サイトメガロウイルスの治療のための組成物及び方法
KR102146340B1 (ko) * 2012-03-27 2020-08-24 배리에이션 바이오테크놀로지스 아이엔씨. 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100267583A1 (en) 2009-04-15 2010-10-21 Variation Biotechnologies Inc. Method and kit for detection of hepatitis a virus neutralizing antibodies

Also Published As

Publication number Publication date
CN119716047A (zh) 2025-03-28
MX2014011504A (es) 2015-03-13
WO2013144722A3 (en) 2013-11-28
EP3613431A1 (en) 2020-02-26
US10006096B2 (en) 2018-06-26
EP3613431B1 (en) 2023-01-11
EP2831285A4 (en) 2015-10-28
JP2015518140A (ja) 2015-06-25
US10161010B2 (en) 2018-12-25
JP6265344B2 (ja) 2018-01-24
KR20140146630A (ko) 2014-12-26
BR112014023913B1 (pt) 2022-08-09
AU2013239383B2 (en) 2018-10-04
US20180274044A1 (en) 2018-09-27
AU2018271276A1 (en) 2018-12-20
CA2867789A1 (en) 2013-10-03
CA2867789C (en) 2022-06-14
RU2014142815A (ru) 2016-05-20
EP2831285A2 (en) 2015-02-04
RU2660712C2 (ru) 2018-07-09
KR102314245B1 (ko) 2021-10-20
CN104321444A (zh) 2015-01-28
AU2018271276B2 (en) 2021-06-03
US20150044668A1 (en) 2015-02-12
EP2831285B1 (en) 2019-10-30
BR112014023913A2 (enExample) 2017-06-20
AU2013239383A1 (en) 2014-10-16
KR20200095575A (ko) 2020-08-10
WO2013144722A2 (en) 2013-10-03
MX354822B (es) 2018-03-21

Similar Documents

Publication Publication Date Title
KR102314245B1 (ko) 항-사이토메갈로바이러스 중화 항체를 탐지하기 위한 방법
Sanchez-Felipe et al. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
De Jong et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine
Graham et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial
Ye et al. Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals
US20230338515A1 (en) Vaccines against coronavirus and methods of use
US20240366754A1 (en) Pharmaceutical compositions for delivery of viral antigens and related methods
Aspden et al. Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector
Antonis et al. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge
Zsak et al. Release of pseudorabies virus from infected cells is controlled by several viral functions and is modulated by cellular components
CN113164585A (zh) 用于预防或治疗巨细胞病毒的先天性感染的疫苗
MX2008011245A (es) Metodos y composiciones para la proteina a35r de virus de enfermedades pustulosas.
EP2267120B1 (en) Recombinant vaccinia virus having hepatitis c virus gene
Hukkanen et al. Simian varicella virus in pigtailed macaques (Macaca nemestrina): clinical, pathologic, and virologic features
CN109476708A (zh) 针对致关节炎甲病毒的疫苗
Swayze et al. Envelope protein E1 as vaccine target for western equine encephalitis virus
Zhou Human cytomegalovirus envelope glycoprotein B as pathogenicity factor for congenital infection
WO2025250534A1 (en) T cell targets for tuberculosis vaccines
CN117186192A (zh) 口蹄疫病毒t细胞抗原表位筛选和应用
O'Connor Structural and Proteomic Analyses of the Gammaherpesviruses KSHV and RRV
JP2021525535A (ja) ウイルス粒子ベースのワクチン
BR112014005404B1 (pt) Citomegalovírus (cmv) defectivo em replicação condicional, composição, uso da composição, método para preparo de cmv defectivo em replicação condicional, e, uso do cmv defectivo em replicação condicional

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250814

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250814

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250814